Sirona Biochem Corp. provide update on Sirona's current activities and anticipated developments for 2019. The proof of concept clinical trial for Sirona's skin lightening compound TFC-1067 began on 26th November 2018 at a center in North Carolina under the supervision of top dermatologist, Dr. Zoe Draelos. The double-blinded trial will assess the safety and efficacy of TFC-1067 in lightening the skin of patients with melasma as well as balancing overall skin tone. The study will end late February. Sirona management expect to receive results 1-2 weeks after the trial is completed. One of the largest US cosmetic companies has invested significant time and resources to evaluate TFC-1067. Their due diligence has included months of research and a substantial investment of resources. The company have met with, and presented to, the management and founders of the company and they remain excited about incorporating Sirona's compound into their existing product line. With this progress to date, the company anticipate licensing discussions to follow the clinical trial. However, to mitigate risk and maximize opportunity, they have maintained communication with a number of leading cosmetic companies around the world and have developed many new contacts. The company have established and continue to build a list of companies eagerly awaiting the results of its clinical trial. This includes its efforts in Japan through its Tokyo based consultant. The global skin lightening market is estimated to grow to USD 31.2 billion by 2024. Of this, Asia makes up the and growing market. However, there remain health concerns over many of the currently available lighteners due to the sensitivity of Asian skin. Accordingly, the company have chosen to enter this market separately from the global licensing strategy so the company can maximize the commercial opportunity while providing a safe, effective product for the Asian skin-type. After many months in China exploring numerous opportunities, its advisor, PRC Partners, has established, and greatly progressed, a relationship in China with a large cosmetic distribution company. The company have signed a memorandum of understanding to work with this distribution company. This company is currently managing and funding a 3-site, 60-person, clinical trial for TFC-1067 which is well underway with preliminary results anticipated mid-February. The trial is comparing TFC-1067 to brands local to the Chinese market and will provide an assessment of the effects of TFC-1067 on Asian skin. Based on the company scientific knowledge of TFC-1067, the company believe the company skin lightener will avoid sensitivity and efficacy issues currently associated with existing skin lighteners. The distributor is contemplating making a significant equity investment in Sirona pending positive results of their testing. The company with the work that PRC has done in China and it will continue to update its shareholders as the trial and agreements advance.